Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.ONS · Entity 608 | Director | October 31, 2017 | November 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date October 31, 2017 · Filed November 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2027-10-31 | Direct | 25,000 |
Reported balance
After 2017-10-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-31 · Grant · Acquired 25,000 · Balance 25,000 F1: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on October 31, 2020, subject to the Reporting Person providing continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on October 31, 2020, subject to the Reporting Person providing continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2017 Filed Nov 2, 2017 22:13 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-17-058967 · doc4.xml · derivative · entry 1 Albrecht Claudio · CIK 0001718003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-10-31 F1 · derivative.exercise_date: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on October 31, 2020, subject to the Reporting Person providing continued service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.